# A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

> **NCT06277219** · PHASE1,PHASE2 · RECRUITING · sponsor: **Latticon Antibody Therapeutics, Inc** · enrollment: 150 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** LAT010
- **DRUG:** LAT010 + ICI

## Key facts

- **NCT ID:** NCT06277219
- **Lead sponsor:** Latticon Antibody Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-05
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06277219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06277219, "A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06277219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*